Eli Lilly and Company (LLY) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strongest combination of fundamentals, catalysts, and momentum: Q1 2026 revenue rose 56%, adjusted EPS jumped 156%, guidance was raised, obesity portfolio access improved via major PBM coverage, Phase 3 retatrutide data were positive, and the stock is up about 22% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin expansion ⢠Debt burden ⢠Strong cash flow LLY remains an elite cash-generating, highly profitable business with improving quarterly margins, but elevated leverage, only moderate liquidity, and a very rich valuation limit the margin of safety.
Price Behavior
Key Price Behavior Insights: ⢠Higher-high trend ⢠Shallow pullbacks ⢠Near-term resistance Support Level: $1,125-$1,131 Resistance Level: $1,160.95 LLY has stayed in a strong last month uptrend with higher highs and higher lows, but near-term upside may be capped unless it breaks above the $1,160.95 resistance while holding $1,125-$1,131 support.
Sentiment & News
Key News Insights: ⢠Earnings beat ⢠Obesity-drug expansion ⢠Clinical upside LLY's strong Q1 beat, raised guidance, expanding obesity-drug coverage, and encouraging phase III data drove repeated new highs and reinforced its growth momentum despite valuation concerns.
AI Summary
LLY is evolving from a pure GLP-1 winner into a broader metabolic/biopharma platform, but with the stock priced for near-flawless execution at ~47x earnings, the key takeaway is that upside now depends on Lilly defending pricing, scaling supply, and proving next-wave pipeline assets can diversify growth fast enough to justify the premium.
Description
Eli Lilly and Company discovers, develops and commercializes prescription medicines worldwide, with established franchises in diabetes, oncology, immunology and central nervous system disorders. Its portfolio includes branded insulin and non-insulin therapies, oncology agents across multiple tumor types, treatments for autoimmune and psychiatric conditions, and respiratory and anti-infective products; the company also maintains collaborations with several biotech and pharmaceutical partners. Founded in 1876, Lilly is headquartered in Indianapolis and operates globally.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 8 | Jun 15 | LLY | Eli Lilly and Company | Strongest combination of fundamentals, catalysts, and momentum: Q1 2026 revenue rose 56%, adjusted EPS jumped 156%, guidance was raised, obesity portfolio access improved via major PBM coverage, Phase 3 retatrutide data were positive, and the stock is up about 22% over 21 trading days. | Active | -1.4% |
| May 27 | Jun 3 | LLY | Eli Lilly and Company | Large-cap healthcare momentum with strong fundamentals: Q1 revenue grew 56% to $19.8B, full-year guidance was raised, Mounjaro and Zepbound demand remains strong, and recent FDA/pipeline/acquisition news keeps catalyst flow active. | Closed | -0.5% |
| May 12 | May 19 | LLY | Eli Lilly and Company | Healthcare selection with strong catalyst flow: Q1 2026 revenue rose 56%, management raised guidance, Foundayo received FDA approval and launched in the U.S., and positive Phase 3 data for retatrutide and Jaypirca add near-term pipeline support. | Closed | +3.4% |
| Feb 9 | Feb 16 | LLY | Eli Lilly and Company | High-quality growth stock with near-term catalysts including strong Q4 2025 revenue and EPS growth, positive Phase 3 data on weight-loss and oncology drugs, significant capital investments, and upcoming regulatory decisions. Technical signals indicate consolidation with steady momentum supporting tactical buying opportunities. | Closed | -0.3% |
| Jan 15 | Jan 22 | LLY | Eli Lilly and Company | Eli Lilly (LLY) is positioned for steady short-term growth with outstanding Q3 2025 earnings showing 54% revenue growth, strong free cash flow, and pipeline innovations including the upcoming launch of orforglipron. Strategic acquisitions and AI-powered partnerships augment its healthcare leadership. The stock shows moderate positive technical momentum, supporting its status as a hot idea amid healthcare innovation despite valuation caution. | Closed | +5.3% |